Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.65B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 2.43M
Average 3.70M
RLAY Total Non-current Liabilities
All obligations due after more than one year.
Relay Therapeutics, Inc.NASDAQ: RLAY
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities falls 13.1% from a year ago
Total non-current liabilities stood at $26.64M at the end of Q2 FY2026, down 13.1% from a year earlier and down 3.7% from the prior quarter. Over 3 fiscal years it compounded at -30.6% a year.
Context
- Total non-current liabilities amounted to 2.8% of total assets at the end of Q2 FY2026, down 1.5 pp from a year earlier.
- Total non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -13.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 28.69M USD
- Year-over-year change
- -32.9%
- 4-year CAGR
- -24.1%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.69M | -32.9% |
| FY2024 | 2024-12-31 | 42.78M | -30.7% |
| FY2023 | 2023-12-31 | 61.71M | -28.1% |
| FY2022 | 2022-12-31 | 85.84M | -0.5% |
| FY2021 | 2021-12-31 | 86.31M | — |
Total Non-current Liabilities vs competitors
How RLAY compares with its peers on the latest reported figures
- RLAY's Jun 2026 total non-current liabilities of $26.64M is the 7th highest of the 11 companies compared; the peer median is $28.19M.
- Its year-over-year change of -13.1% is the 9th highest of 10, against a peer median of -8.5%.
- Total non-current liabilities amounts to 2.8% of total assets for RLAY, versus a peer median of 3.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.36B | +259.0% | +88.4% | 31.5% | |
| Aug 2026 | $96.25M | +41.8% | +14.1% | 8.1% | |
| Jun 2026 | $64.86M | -10.0% | +24.3% | 3.9% | |
| Sep 2026 | $38.21M | -12.8% | -7.9% | 3.8% | |
| Mar 2026 | $28.25M | +10.1% | +59.5% | 2.7% | |
| Sep 2026 | $28.12M | -11.2% | -38.3% | 2.7% | |
| Jun 2026 | $26.64M | -13.1% | -30.6% | 2.8% | |
| Mar 2026 | $17.74M | -3.0% | +80.3% | 14.8% | |
| Mar 2026 | $5.21M | -8.5% | +26.3% | 1.3% | |
| Mar 2026 | $3.43M | -37.6% | -21.0% | 0.8% | |
| Mar 2026 | $320K | — | — | 0.1% | |
| Peer median (excluding RLAY) | $28.19M | -8.5% | +24.3% | 3.3% | |
Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 280.12M | 151.79M | 143.74M | 124.29M | 84.02M |
| Short-term Investments | 677.95M | 847.12M | 606.35M | 657.04M | 470.5M |
| Net Receivables | 4.94M | 5.22M | 0 | 0 | 0 |
| Inventory | 0 | 12.11M | 0 | 0 | 0 |
| Other Current Assets | 1.76M | 3.26M | 3.32M | 10.53M | 5.97M |
| Total Current Assets | 976.24M | 1.02B | 770.1M | 809.2M | 578.28M |
| Property, Plant & Equipment (Net) | 27.32M | 75.39M | 68.87M | 57.67M | 41.72M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.3M | 2.3M | 2.3M | 2.3M | 0 |
| Long-term Investments | 0 | 2.58M | 2.71M | 0 | 1.34M |
| Tax Assets | 0 | (2.58M) | 0 | 0 | 0 |
| Other Non-current Assets | 2.58M | 2.58M | 0 | 2.12M | 0 |
| Total Non-current Assets | 32.2M | 80.27M | 73.88M | 62.09M | 43.05M |
| Total Assets | 1.01B | 1.1B | 843.98M | 871.3M | 621.33M |
| Account Payables | 8.28M | 10.58M | 9.21M | 14.1M | 7.71M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 248K | 0 | 0 | 7.68M | 0 |
| Other Current Liabilities | 989K | 26.15M | 1.91M | 2.1M | 463K |
| Total Current Liabilities | 24.32M | 63.71M | 30.27M | 50.73M | 25.58M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 65.26M | 32.38M | 13.21M | 0 | 0 |
| Total Non-current Liabilities | 86.31M | 85.84M | 61.71M | 42.78M | 28.69M |
| Total Liabilities | 110.64M | 149.55M | 91.98M | 93.5M | 54.27M |
| Common Stock | 109K | 121K | 127K | 168K | 168K |
| Retained Earnings | (768.1M) | (1.06B) | (1.4B) | (1.74B) | (2.01B) |
| Accumulated OCI | (1.09M) | (10.42M) | (196K) | (991K) | 733K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 897.81M | 950.22M | 752M | 777.79M | 567.06M |
| Total Debt | 22.9M | 57.74M | 53.47M | 48.5M | 32.46M |
| Net Debt | (257.22M) | (94.05M) | (90.27M) | (75.79M) | (51.56M) |
Relay Therapeutics, Inc.
NASDAQ:RLAY
Intrinsic Alpha fair value
Locked
Current Price
$16.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.